These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34908838)

  • 1. Cariprazine in Three Special Different Areas: A Real-World Experience.
    Gesi C; Paletta S; Palazzo MC; Dell'Osso B; Mencacci C; Cerveri G
    Neuropsychiatr Dis Treat; 2021; 17():3581-3588. PubMed ID: 34908838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
    Veselinović T; Paulzen M; Gründer G
    Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies.
    Barabássy Á; Sebe B; Acsai K; Laszlovszky I; Szatmári B; Earley WR; Németh G
    Neuropsychiatr Dis Treat; 2021; 17():957-970. PubMed ID: 33854317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.
    Citrome L
    Neuropsychiatr Dis Treat; 2018; 14():2563-2577. PubMed ID: 30323605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine.
    Werner FM; Coveñas R
    Ther Clin Risk Manag; 2015; 11():1657-61. PubMed ID: 26586950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia.
    Caccia S; Invernizzi RW; Nobili A; Pasina L
    Ther Clin Risk Manag; 2013; 9():319-28. PubMed ID: 23966785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine: First Global Approval.
    McCormack PL
    Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
    Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials.
    Do A; Keramatian K; Schaffer A; Yatham L
    Front Psychiatry; 2021; 12():769897. PubMed ID: 34970166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on schizophrenia and bipolar disorder: focus on cariprazine.
    Roberts RJ; Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Neuropsychiatr Dis Treat; 2016; 12():1837-42. PubMed ID: 27524901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.
    Selvan P; Devkare P; Shetty A; Dharmadhikari S; Khandhedia C; Mane A; Mehta S; Andrade C
    Front Psychiatry; 2024; 15():1385925. PubMed ID: 38711874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine for the Treatment of Bipolar Disorder.
    Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
    Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
    CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.